Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension
Introduction: Hypertension, “The silent killer” is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. Aim: The current study aims to a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2014-06-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/4419/7728_CE(RA)_F(T)_PF1(PAK)_PFA(AK)_PF2(AGAK)_PF2(PN).pdf |
| _version_ | 1818316615250345984 |
|---|---|
| author | Vivek V. Bhosale S.C. Inamdar Karande V.B. Burute S.R. Murthy M.B. Ghatak A. |
| author_facet | Vivek V. Bhosale S.C. Inamdar Karande V.B. Burute S.R. Murthy M.B. Ghatak A. |
| author_sort | Vivek V. Bhosale |
| collection | DOAJ |
| description | Introduction: Hypertension, “The silent killer” is a multifactorial
disorder which is asymptomatic and if left untreated leads to lethal
complications. Nebivolol is a third generation beta blocker with
additional vasodilating property due to nitric oxide release.
Aim: The current study aims to assess efficacy and safety of
Nebivolol and compare with Atenolol.
Materials and Methods: This was prospective, double blind,
comparative controlled clinical study. Total 90 patients were enrolled
into study as per selection criteria. Patients were randomized to
receive Atenolol and Nebivolol with 45 patients in each group for
12 weeks.
Results and Conclusion: The mean reduction diastolic blood
pressure in Nebivolol and Atenolol group was 10.77±2.60 and
10.05±2.83 respectively. The number of patients with adverse effect
events was higher in the Atenolol than in the Nebivolol group (36.84%
of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that,
for the same antihypertensive effect, Nebivolol was better tolerated
than Atenolol. |
| first_indexed | 2024-12-13T09:24:15Z |
| format | Article |
| id | doaj.art-b4ad02a7c2ee4356b68be41d59e26065 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-13T09:24:15Z |
| publishDate | 2014-06-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-b4ad02a7c2ee4356b68be41d59e260652022-12-21T23:52:40ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2014-06-0186HC01HC0410.7860/JCDR/2014/7728.4419Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential HypertensionVivek V. Bhosale0S.C. Inamdar1Karande V.B.2Burute S.R.3Murthy M.B.4Ghatak A.5Scientist, Clinical and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, India.Associate Professor, Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India. Lecturer, Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India. Lecturer, Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India. Lecturer, Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India.Chief Scientist, Clinical and Experimental Meidcine, CSIR-Central Drug Research Institute, Lucknow, India.Introduction: Hypertension, “The silent killer” is a multifactorial disorder which is asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third generation beta blocker with additional vasodilating property due to nitric oxide release. Aim: The current study aims to assess efficacy and safety of Nebivolol and compare with Atenolol. Materials and Methods: This was prospective, double blind, comparative controlled clinical study. Total 90 patients were enrolled into study as per selection criteria. Patients were randomized to receive Atenolol and Nebivolol with 45 patients in each group for 12 weeks. Results and Conclusion: The mean reduction diastolic blood pressure in Nebivolol and Atenolol group was 10.77±2.60 and 10.05±2.83 respectively. The number of patients with adverse effect events was higher in the Atenolol than in the Nebivolol group (36.84% of Atenolol Vs 12.82% of Nebivolol). Thus it can be concluded that, for the same antihypertensive effect, Nebivolol was better tolerated than Atenolol.https://jcdr.net/articles/PDF/4419/7728_CE(RA)_F(T)_PF1(PAK)_PFA(AK)_PF2(AGAK)_PF2(PN).pdfhypertensionnebivololatenolol |
| spellingShingle | Vivek V. Bhosale S.C. Inamdar Karande V.B. Burute S.R. Murthy M.B. Ghatak A. Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension Journal of Clinical and Diagnostic Research hypertension nebivolol atenolol |
| title | Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension |
| title_full | Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension |
| title_fullStr | Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension |
| title_full_unstemmed | Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension |
| title_short | Beneficial Effects of Nebivolol in Comparison with Atenolol on Safety and Tolerability in Essential Hypertension |
| title_sort | beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension |
| topic | hypertension nebivolol atenolol |
| url | https://jcdr.net/articles/PDF/4419/7728_CE(RA)_F(T)_PF1(PAK)_PFA(AK)_PF2(AGAK)_PF2(PN).pdf |
| work_keys_str_mv | AT vivekvbhosale beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension AT scinamdar beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension AT karandevb beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension AT burutesr beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension AT murthymb beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension AT ghataka beneficialeffectsofnebivololincomparisonwithatenololonsafetyandtolerabilityinessentialhypertension |